About Blood Immunology & Cellular Therapy

Blood Immunology & Cellular Therapy provides an international platform for publishing original research in basic, translational, and clinical investigations related to cellular and non-cellular immunotherapies for neoplastic conditions and the underlying immunology.

• Non-cellular Therapies: vaccinations, monoclonal antibodies (e.g., bispecific antibodies and BiTEs), antibody-drug conjugates, immune checkpoint inhibitors, and more.
• Cellular Therapies: CAR-T cells, TCR-engineered T-cells, CAR-NK cells, NK cells, T-Regs, mesenchymal stromal cells (MSCs), and more.
• Gene Therapies: vector design, gene editing (CRISPR-Cas9, base editing), and ex-vivo/in-vivo approaches for congenital conditions like primary immune deficiencies, hemoglobinopathies, metabolic disorders and hemophilia, and more.
• Immunological Aspects of Allogeneic-SCT*: graft rejection, graft-versus-leukemia effect, Donor Lymphocyte Infusion (DLI), and graft-versus-host disease.
• Treatment of non-malignant immunologic diseases*: cellular and immunotherapies.
• Other: regulatory and manufacturing issues

*General allogeneic stem cell transplantation and general immunology and non-neoplastic immunologic conditions are not within scope.

If you are uncertain whether your work is within the scope of the journal, please submit a Presubmission Inquiry containing a cover letter and an abstract of the manuscript. Whole manuscripts will not be considered. Presubmission inquiries are managed via the manuscript submission system. Once in the system, select ‘Submit Manuscript’ and then ‘Presubmission Inquiry.’